Benchmark restated a buy rating on Rambus shares.
2 reports, 1 independent
Updated Sep 13
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Benchmark restated a buy rating on Rambus shares.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
Related events
- MarketBeat provided analyst ratings and compared the stock volatility of Rambus and ACM Research against the S&P 500.
- Benchmark reaffirmed a buy rating on the stock of Alpha Tau Medical.
- Benchmark and TD Cowen reissued buy ratings on Strive shares on June 30, 2026.
- Benchmark reduced its price target and set a buy rating for Abbott Laboratories, while Royal Bank of Canada issued an outperform rating on July 29, 2026.